Developmental Toxicity Study of DL-4-Hydroxy-4-Phenylhexanamide (DL-HEPB) in Rats

Autor: José Melesio Cristóbal-Luna, María Angélica Mojica-Villegas, Sergio Enrique Meza-Toledo, Yuliana García-Martínez, Angélica Pérez-Juárez, Germán Chamorro-Cevallos
Jazyk: angličtina
Rok vydání: 2023
Předmět:
Zdroj: Life, Vol 13, Iss 8, p 1714 (2023)
Druh dokumentu: article
ISSN: 2075-1729
DOI: 10.3390/life13081714
Popis: Antiepileptic drugs affect embryonic development when administered during pregnancy, generating severe alterations, such as as cleft lip, spina bifida, heart abnormalities, or neuronal alterations. The compound DL-4-hydroxy-4-phenylhexanamide (DL-HEPB), a phenyl alcohol amide structurally different from known anticonvulsants, has shown good anticonvulsant effects in previous studies. However, its effects on intrauterine development are unknown. So, the purpose of this study was to determine the potential of DL-HEPB to produce alterations in conceptus. Pregnant Wistar rats were orally exposed to 0, 50, 100, and 200 mg/kg of DL-HEPB during organogenesis, and their food consumption and weight gain were measured. On gestation day 21, pregnant females were euthanized to analyze the fetuses for external, visceral, and skeletal malformations. A significant decrease in food consumption and body weight was observed in mothers, without any other manifestation of toxicity. In fetuses, no external malformations, visceral, or skeletal abnormalities, were observed under the dose of 100 mg/kg, while the dose of 200 mg/kg caused malformations in low frequency in brain and kidneys. In view of the results obtained, DL-HEPB could be a good starting point for the design of new highly effective anticonvulsant agents, with much lower developmental toxicity than that shown by commercial anticonvulsants.
Databáze: Directory of Open Access Journals
Nepřihlášeným uživatelům se plný text nezobrazuje